NEW

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share in cash, corresponding to an enterprise value of...

Medline Expands Catheter Portfolio

Medline and Consure Medical have announced a new agreement for Medline to exclusively distribute the QiVi MEC male external urine management device to help guard against catheter-associated urinary tract infections (CAUTI) and incontinence-associated dermatitis (IAD)....

FDA Clears Single-use Flexible Ureteroscope

Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later...

Brainlab, Fujifilm Offer Advanced Neurosurgery Capabilities

FUJIFILM Healthcare Americas Corporation and Brainlab recently announced that Brainlab will be the exclusive U.S. distributor of ARIETTA Precision Ultrasound for neurosurgery applications to be utilized with Brainlab’s surgical navigation systems. ARIETTA Precision,...

Study: Prophylactic Dressings Reduce Pressure Injuries

A new study shows a clear association between the prophylactic use of five-layer foam sacral dressings and reductions in pressure injury rates. Specifically, the study looked at the prophylactic use of Mölnlycke’s Mepilex Border Sacrum dressing in the acute care setting over a six-year period (2010-2015).

The study, “Effectiveness and Value of Prophylactic 5-Layer Foam Sacral Dressings to Prevent Hospital-Acquired Pressure Injuries in Acute Care Hospitals – an Observational Cohort Study” was conducted by William V. Padula, Ph.D., MS, MSc; Assistant Professor, Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health. It was published in the September/October 2017 Journal of Wound, Ostomy & Continence Nursing and is available online.

The study used billing claims data to evaluate the real-world effectiveness of a prophylactic dressing at reducing hospital-acquired pressure injury rates in 1.03 million patients treated at 38 academic medical centers and member institutions of the University Health System Consortium. No other prophylactic dressing has such extensive, real-world evidence to support its use in pressure ulcer prevention programs.

The study found significant pressure injury rate reductions following the prophylactic adoption of Mepilex Border Sacrum dressings, concluding that they were an effective component of a pressure injury prevention protocol. On average, hospitals using a typical quantity of 1-2 dressings per hospitalized patient admission experienced a 1.0 case reduction per quarter in pressure injuries identified by Patient Safety Indicator #3 (PSI-03), which is made up of Hospital Acquired Pressure Injuries (HAPI) stages 3, 4 and unstageable. These stages of pressure ulcers are the most dangerous for patients and the most expensive to treat.

One of the most significant findings of the study was that hospitals investing in Mepilex Border Sacrum dressings for prophylactic use at a rate of one dressing per patient made a 100 percent return on investment in less than one year (not including litigation costs). Across the study population, spending on pressure injury treatment decreased from $120/patient to $43/patient, while investment in prophylactic dressings increased from $2.60/patient to $20/patient.

Since the average estimated cost of a PSI-03 ranges from $50,000 to $150,000, the study reveals that the prophylactic use of Mepilex Border Sacrum dressings could save hospitals $200,000 to $600,000 per year in expenses associated with pressure injuries, as well as avoidance of CMS penalties for high hospital-acquired condition rates.

Previous

Next

1 Comment

  1. A really good research and very useful information. Thanks, a lot for sharing it.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

X